Liberalization has changed the way organizations are working. To be competitive, organizations have taken recourse to reduce the cost of production which is undertaken by the reduction in overhead costs. This has led to both positive and negative outcomes. The article takes the help of literature from all over to examine the effects of downsizing especially on the survivors and discusses the strategies for their successful handling. At the end it tries to develop a model mentioning the effect of downsizing on survivors and strategies to handle them.
The disease Amlapitta is a common functional disease of Annavaha Srotas. Materialistic life style provoke people to run behind a busy, stressful life which is least concern towards proper food habits. "Hurry","Worry" & "Curry" are the main causes for disease Amlapitta. Amlapitta is a disease prevalent all over the world. The increasing prevalence rate is a constant challenge to the research workers. So here an attempt has been made to analyze the research work about to manage Amlapitta. In this article, systemic review of 4 research (held at Government Ayurved College & Hospital, Nanded) had been carried out.
Fragile X syndrome is a common condition resulting from a cytogenetic abnormality in the X chromosome. Mental retardation, characteristic facies, and large testes are some of the most important characteristics of the condition. The relatively high incidence of the syndrome—approximately one per thousand—the high incidence of cardiac anomalies in these individuals, the oral and facial features associated with the condition, and the paucity of reported cases in the dental literature make it particularly interesting to dentistry. Here we report the case of a 12‐year‐old male, including the cytogenetic and cephalometric analyses, presenting with some of the classic features and some features not commonly reported
The disease Amlapitta is a common functional disease of Annavaha Srotas. Materialistic life style provoke people to run behind a busy, stressful life which is least concern towards proper food habits. "Hurry","Worry" & "Curry" are the main causes for disease Amlapitta. Amlapitta is a disease prevalent all over the world. The increasing prevalence rate is a constant challenge to the research workers. So here an attempt has been made to analyze the research work about to manage Amlapitta. In this article, systemic review of 4 research (held at Government Ayurved College & Hospital, Nanded) had been carried out.
Department of Chemistry, Karnatak University, Dharwad-580 003 Government College of Pharmacy, Bangalore-560 001 Manuscript received 26 June 1994, revised 24 November 1994, accepted 12 January 1995 Synthesis, Reactions, Mass Spectra and Biological Evaluation of some New 4-Aryloxymethylcarbostyrils.
AIM: A comparative study of Mocharasa siddhatail and Mahamasha tail Nasya in Vishvachi.Objective: To study the efficacy of Mocharasa Taila Nasya in Vishvachi, compare effect of Mocharasa Taila with Mahamasha Taila, and to Study Literary explanation of Vishvachi Vyadhi.Method: Randomized single blind comparative clinical trial on 40 patients having Vishvachi and were selected for the study randomly. 20 patients were selected and treated as study group A with Mocharasa Taila for 14 days and 20 patients were selected and treated as group B with Mahamasha taila.Mocharasa taila: Authentication of Mocharasa was done in department of botany at Pune University. Standardisation of Mocharasa taila was done in Department of Rasa shastra Bhaishajakalpana vigyan at Bharati Ayurved College. Mahamasha Taila is prepared from Shankar pharmacy (GMP certify no.GA/1153 Government of Gujarat drug control administration) according to Bhaishjya Ratnavali.Follow up: 0th, 7th, 14th, 15th day.Duration: Total duration study was 14 days. This study was carried out in Bharati Vidyapeeth Deemed University College of Ayurved & Hospital Pune in Year 2010 and 2011.Results: Comparing Mocharasa taila and Mahamasha taila Nasya and are equally effective in Vishvachi.Statistical Analysis: Statistical analysis shows that Mocharasa taila and Mahamasha taila are equally effective in symptoms such as Bahu Shoola, Bahu badhirya & Bahu chesta apaharana.Conclusion: Mocharasa taila and Mahamasha taila Nasya is equally effective in Vishavchi.
Background: Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods: Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings: Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation: The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC.
